MANAC Chemical Partners Co.,Ltd
Notice of Revision to Full-Year Consolidated Earnings Guidance for the Fiscal Year Ending March 2027
Revised net sales to 12,500 hundred million yen (previous forecast: 11,600 hundred million yen), operating income to 1,100 million yen, ordinary income to 1,250 million yen, net income attributable to owners of parent to 950 million yen, and net income per share to 115.23 yen. This is not a dividend increase or a change to the year-end dividend forecast; overall profitability is expected to improve due to supply-demand improvement and the start of mass production of newly developed products.
Key Figures
- Net Sales: 12,500 hundred million yen
- Operating Income: 1,100 million yen
- Ordinary Income: 1,250 million yen
AI要約
Summary of Revision to Earnings Guidance
Increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, along with the start of mass production and increased overseas sales of newly developed semiconductor-related products, are expected to contribute to net sales exceeding the previous forecast. Profit estimates have also become reasonably calculable, and revised forecasts for each profit item are being disclosed. Both net sales and profits are expected to exceed the results of the previous fiscal year.
Outlook and Cautionary Matters
This document contains forecasts based on information available at the time and actual results may differ depending on future market trends. The reasons for the revision include increased demand and the start of mass production of newly developed products, as well as expansion in overseas markets.
MANAC Chemical Partners Co.,Ltd
Company overview · Stock price · Financial data · All IR
